Which drug received FDA approval as a first-in-class targeted therapy
Which drug received FDA approval as a first-in-class targeted therapy for metastatic pancreatic cancer? The FDA approved Rasonque (daraxonrasib) on August 26, 2026, for eligible adults with metastatic pancreatic adenocarcinoma. This important healthcare and science current affairs question is useful for SSC, UPSC, Banking, Railway, Defence and other competitive exams. Test your knowledge, comment your answer, save this MCQ for revision, and follow for more Daily Current Affairs and GK Questions.
current affairs, current affairs 2026, current affairs mcq, Rasonque, daraxonrasib, FDA approval 2026, pancreatic cancer treatment, pancreatic cancer drug, targeted therapy, metastatic pancreatic cancer, FDA current affairs, healthcare current affairs, science current affairs, SSC current affairs, UPSC current affairs
#CurrentAffairs #CurrentAffairs2026 #ScienceCurrentAffairs #GKQuestions #CompetitiveExams
Newsletter
Recent Posts
Insurance Career in India: Skills, Opportunities and How to Build a Successful Career
The insurance industry is one of the important pillars of
Salesforce Career Guide: Skills, Training and Job Opportunities in the Salesforce Ecosystem
Salesforce has become a leading cloud-based Customer Relationship Management
Which drug received FDA approval as a first-in-class targeted therapy
Which drug received FDA approval as a first-in-class targeted therapy
Which Country Is Strengthening Its Domestic Defence Industry to Reduce Reliance on the U.S.?
Which country is strengthening its domestic defence industry to reduce